This Schedule 14A filing consists of communications from Paratek Pharmaceuticals, Inc., a Delaware corporation (the “Company”), to the Company’s employees relating to the Agreement and Plan of Merger, dated as of June 6, 2023, by and among the Company, Resistance Acquisition, Inc., a Delaware corporation (“Parent”) and Resistance Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (the “Merger Agreement”).
The following email was sent from the Company’s Chief Executive Officer to Company employees on June 6, 2023:
Employee Email Announcing Transaction
GPC and Novo – Paratek Announcement – June 6, 2023
Subject: Important Paratek News Today
Dear Paratek Team,
This morning we announced that entities affiliated with Gurnet Point Capital (GPC), a private equity firm headquartered in Cambridge, Mass. and Novo Holdings (Novo), a holding and investment company responsible for managing the assets and wealth of the Novo Nordisk Foundation, have entered into an agreement to acquire Paratek, which, if consummated, would result in such entities gaining full ownership of the company and NUZYRA® (omadacycline) while taking the company private. The press release we issued is posted on our website and can be accessed here.
We believe this strategic transaction offers our best opportunity to maximize shareholder value, including the opportunity to benefit from the future value created by NUZYRA through the CVR.
Importantly, this agreement is firm recognition of the foundational value everyone on our team has helped to create with a strong NUZYRA business today.
A significant amount of thought and consideration went into this decision. Both GPC and Novo have distinguished records of successful partnerships in the life sciences sector and have been recognized for executing on their commitments to invest in growth, both near-term and long-term. Importantly, they bring deep experience and expertise to our already talented team, and we are excited to partner with them.
At this transition point in Paratek’s journey, I thank you all for your commitment and dedication to our important mission. We should all be proud of what we have accomplished to date, and we look forward to having an even stronger foundation to continue to serve patients and healthcare providers through providing NUZYRA, our hard work and shared passion for addressing difficult-to-treat infections and saving lives.
We know that changes like this bring uncertainty and many questions. As always, our executive team is committed to supporting you at every step of this process over the next few months. We pledge to do our best to provide information as we have more information to share as decisions are made.
To address initial questions, we invite you to participate in a virtual town hall meeting later this morning at 10:30 a.m. ET to discuss this announcement in more detail.
Until the transaction closes, which we expect to happen in the third quarter, it is business as usual. The transaction is subject to regulatory reviews and other customary closing conditions. Thank you in advance for your patience and flexibility during this transition.
I look forward to our meeting to discuss today’s news. Be on the lookout for a calendar invite shortly with the meeting details.
Evan